Clinicopathological indices to predict hepatocellular carcinoma molecular classification.

ABSTRACT:

Background & aims

Hepatocellular carcinoma (HCC) is the second most lethal cancer caused by lack of effective therapies. Although promising, HCC molecular classification, which enriches potential responders to specific therapies, has not yet been assessed in clinical trials of anti-HCC drugs. We aimed to overcome these challenges by developing clinicopathological surrogate indices of HCC molecular classification.

Methods

Hepatocellular carcinoma classification defined in our previous transcriptome meta-analysis (S1, S2 and S3 subclasses) was implemented in an FDA-approved diagnostic platform (Elements assay, NanoString). Ninety-six HCC tumours (training set) were assayed to develop molecular subclass-predictive indices based on clinicopathological features, which were indepe

SUBMITTER: Tan PS 

PROVIDER: S-EPMC4674393 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature